Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ANIP

ANIP - ANI Pharmaceuticals Inc Stock Price, Fair Value and News

$70.36-2.13 (-2.94%)
Market Closed

82/100

ANIP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

82/100

ANIP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANIP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANIP Price Action

Last 7 days

-5.0%

Last 30 days

-7.7%

Last 90 days

-12.5%

Trailing 12 Months

14.5%

ANIP RSI Chart

ANIP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANIP Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

20.2

Price/Sales (Trailing)

1.79

EV/EBITDA

7.45

Price/Free Cashflow

9.23

ANIP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ANIP Fundamentals

ANIP Revenue

Revenue (TTM)

883.4M

Rev. Growth (Yr)

29.64%

Rev. Growth (Qtr)

8.45%

ANIP Earnings

Earnings (TTM)

78.3M

Earnings Growth (Yr)

367.52%

Earnings Growth (Qtr)

3.28%

ANIP Profitability

Operating Margin

90.34%

EBT Margin

10.84%

Return on Equity

14.49%

Return on Assets

5.44%

Free Cashflow Yield

10.83%

ANIP Investor Care

Shares Dilution (1Y)

6.55%

Diluted EPS (TTM)

3.34

ANIP Alerts

  • 6 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025674.1M747.4M826.9M883.4M
2024517.5M539.0M555.5M614.4M
2023358.7M401.4M449.4M486.8M
2022226.1M251.3M283.1M316.4M
2021213.2M213.4M212.5M216.1M
2020203.4M197.5M199.2M208.5M
2019208.0M215.1M215.7M206.5M
2018186.7M189.2M191.7M201.6M
2017144.7M158.1M167.8M176.8M
201678.1M89.9M108.5M128.6M
201563.9M76.7M79.3M76.3M
201435.4M35.9M45.5M56.0M
201317.8M18.7M21.5M30.1M
20125.4M10.4M15.4M20.4M
20112.0M1.5M944.9K435.2K
Get all data in R, Python etc through our Historical Stock Data APIs

About ANI Pharmaceuticals Inc

ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
 CEO
 WEBSITEanipharmaceuticals.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES600

ANI Pharmaceuticals Inc Frequently Asked Questions

ANIP is the stock ticker symbol of ANI Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of ANI Pharmaceuticals Inc is 1.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, ANIP's PE ratio (Price to Earnings) is 20.2 and Price to Sales (PS) ratio is 1.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ANI Pharmaceuticals Inc has provided 0.078 (multiply by 100 for percentage) rate of return.